A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults. (Vaccine, 2016)

(untitled) - Minhinnick, A; Satti, I; Harris, S; Wilkie, M; Sheehan, S; Stockdale, L; Lopez-Ramon, R; Poulton, I; Lawrie, A; Vermaak, S; Le Vert, A; Del Campo, J; et al.